Study to assess improvement in therapeutic outcomes by platelet inhibition with prasugrel

Study to assess improvement in therapeutic outcomes by platelet inhibition with prasugrel

Bibliographic Details
Main Author:	Amit Madaan
Format:	Article
Language:	English
Published:	Elsevier 2015-12-01
Series:	Indian Heart Journal
Online Access:	http://www.sciencedirect.com/science/article/pii/S0019483215007798

Similar Items

Prasugrel
by: Gianluca Airoldi, et al.
Published: (2013-04-01)

Impact of immature platelet fraction on platelet reactivity during prasugrel maintenance treatment
by: Monica Verdoia, et al.
Published: (2019-10-01)

Improving outcomes in patients undergoing percutaneous coronary intervention: role of prasugrel
by: Zuzana Motovska, et al.
Published: (2009-05-01)

Diurnal Variability of Platelet Aggregation in Patients with Myocardial Infarction Treated with Prasugrel and Ticagrelor
by: Piotr Adamski, et al.
Published: (2022-02-01)

Prasugrel-related hepatotoxicity
by: Zeki Dogan, et al.
Published: (2022-10-01)

What is the risk of intensifying platelet inhibition beyond clopidogrel? A systematic review and a critical appraisal of the role of prasugrel.
by: Testa, L, et al.
Published: (2010)

NICHE OF PRASUGREL AMONG OTHER PLATELET P2Y12-RECEPTOR INHIBITORS
by: P. S. LAGUTA, et al.
Published: (2017-12-01)

Impact of Prasugrel and Ticagrelor on Platelet Reactivity in Patients With Acute Coronary Syndrome: A Meta-Analysis
by: Lulu Dai, et al.
Published: (2022-06-01)

Clinical utility of remote platelet function measurement using P-selectin: assessment of aspirin, clopidogrel, and prasugrel and bleeding disorders
by: Philip M Bath, et al.
Published: (2018-07-01)

Use of prasugrel in patients with clopidogrel hypersensitivity
by: Aparna Joshi, et al.
Published: (2022-01-01)

Comparison of platelet reactivity between prasugrel and ticagrelor in patients with acute coronary syndrome: a meta-analysis
by: Mingxiang Wen, et al.
Published: (2020-10-01)

Low-Dose Prasugrel in Treatment of Cerebral Aneurysms
by: Hyun-Seung Kang
Published: (2018-09-01)

Eversion endarterectomy under full prasugrel treatment
by: Thomas Kotsis, et al.
Published: (2017-11-01)

PRASUGREL: FREQUENTLY ASKED QUESTIONS FROM PRACTITIONERS
by: O. O. Shakhmatova, et al.
Published: (2019-06-01)

Platelet reactivity in patients with acute coronary syndrome treated with prasugrel or ticagrelor in comparison to clopidogrel: a retrospective pharmacodynamic analysis
by: Gerhard Selhorst, et al.
Published: (2019-04-01)

Platelet Blockage: Prasugrel versus Ticagrelor: Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment 5
by: Venkatakrishnan Ramakumar
Published: (2019-01-01)

Prasugrel, a Platelet P2Y12 Receptor Antagonist, Improves Abnormal Gait in a Novel Murine Model of Thrombotic Hindlimb Ischemia
by: Kousaku Ohno, et al.
Published: (2016-04-01)

Platelet Inhibition, Endothelial Function, and Clinical Outcome in Patients Presenting With ST‐Segment–Elevation Myocardial Infarction Randomized to Ticagrelor Versus Prasugrel Maintenance Therapy: Long‐Term Follow‐Up of the REDUCE‐MVI Trial
by: Nina W. van der Hoeven, et al.
Published: (2020-03-01)

WHAT ARE THE OPPORTUNITIES OF PRASUGREL IN THE TREATMENT OF PATIENTS WITH ACUTE CORONARY SYNDROME
by: M. Yu. Gilyarov, et al.
Published: (2018-05-01)

Oral antiplatelet therapy in diabetes mellitus and the role of prasugrel: an overview
by: Hillegass B
Published: (2011-07-01)

Differential impact of diabetes mellitus on antiplatelet effects of prasugrel and clopidogrel
by: Satoshi Niijima, et al.
Published: (2018-03-01)

Effect of CYP2C19 status on platelet reactivity in Taiwanese acute coronary syndrome patients switching to prasugrel from clopidogrel: Switch Study
by: Feng-Yu Kuo, et al.
Published: (2022-09-01)

Low-Dose Prasugrel in Patients with Resistance to Clopidogrel for the Treatment of Cerebral Aneurysms
by: Dongwhane Lee, et al.
Published: (2018-09-01)

Prasugrel for the treatment of acute coronary artery syndromes with percutaneous coronary intervention
by: J Greenhalgh, et al.
Published: (2010-05-01)

Prasugrel for the treatment of acute coronary artery syndromes with percutaneous coronary intervention
by: J Greenhalgh, et al.
Published: (2010-05-01)

Use of Clopidogrel, Prasugrel, or Ticagrelor and Patient Outcome after Acute Coronary Syndrome in Austria from 2015 to 2017
by: Safoura Sheikh Rezaei, et al.
Published: (2020-10-01)

Variability of response on prophylactic prasugrel for endovascular treatment of intracranial aneurysms: Clinical implications.
by: Noah Hong, et al.
Published: (2023-01-01)

Biocatalytic Syntheses of Antiplatelet Metabolites of the Thienopyridines Clopidogrel and Prasugrel Using Fungal Peroxygenases
by: Jan Kiebist, et al.
Published: (2021-09-01)

Assessment of Impact of Patient Recruitment Volume on Risk Profile, Outcomes, and Treatment Effect in a Randomized Trial of Ticagrelor Versus Prasugrel in Acute Coronary Syndromes
by: Gjin Ndrepepa, et al.
Published: (2021-11-01)

<b>Development and validation of the discriminating method of prasugrel dissolution in tablets using ultraviolet detection
by: Camila Rigobello, et al.
Published: (2014-10-01)

PRASUGREL FOR THE TREATMENT OF ACUTE CORONARY SYNDROMES AND PERCUTANEOUS CORONARY INTERVENTION: STATUS UPDATE ON THE PROBLEM
by: O. O. Shakhmatova, et al.
Published: (2018-05-01)

Prasugrel Inappropriate Use in Patients Post-percutaneous coronary intervention (PCI). A Single Center Study
by: Ahmed Amro, et al.
Published: (2019-07-01)

Assessment of the U.S. Food and Drug Administration's risk evaluation and mitigation strategy (REMS) for prasugrel (EFFIENT): A narrative review
by: Thomas Metkus, et al.
Published: (2024-02-01)

No Differences in Gastrointestinal Bleeding Risk among Clopidogrel-, Ticagrelor-, or Prasugrel-Based Dual Antiplatelet Therapy
by: Viviana Laredo, et al.
Published: (2020-05-01)

Real‐World Evidence on Disparities on the Initiation of Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndrome
by: Mustafa Yildirim, et al.
Published: (2023-08-01)

Incidence, Predictors, and Clinical Impact of Early Prasugrel Cessation in Patients With ST‐Elevation Myocardial Infarction
by: Konstantinos C. Koskinas, et al.
Published: (2018-04-01)

Erosive arthritis and hepatic granuloma formation induced by peptidoglycan polysaccharide in rats is aggravated by prasugrel treatment.
by: Analia E Garcia, et al.
Published: (2013-01-01)

Thirty day outcomes of Indian patients in a multicenteric hospital registry of patients with acute coronary syndrome (ACS) undergoing PCI treated with prasugrel
by: A. Omar, et al.
Published: (2014-11-01)

Pharmacodynamic comparison of low-dose ticagrelor to low-dose prasugrel in patients with prior myocardial infarction: the ALTIC-2 study
by: Dimitrios Alexopoulos, et al.
Published: (2020-08-01)

The Effect of Ticagrelor on Endothelial Function Compared to Prasugrel, Clopidogrel, and Placebo: A Systematic Review and Meta-Analysis
by: Baoyi Guan, et al.
Published: (2022-01-01)